Cindy Cameronne

The judge overseeing class actions against Hyundai and Kia has taken the parties to task over lack of progress in the cases, calling them out for “paying lip service” to the obligation to proceed expeditiously. 

Meal delivery companies Hello Fresh and Youfoodz say the consumer regulator needs to provide more details in its cases alleging customers were charged a fee after cancelling subscriptions.

A judge has refused to order a competitive tender process for the administration of a $549 million settlement in a class action over the Morrison government’s Robodebt scheme, while also questioning the funder’s bid for a $71 million commission.

A class action on behalf of tens of thousands of KFC workers who were allegedly denied rest breaks has settled for around $29 million. 

Former Carlton president and PwC chief executive officer Luke Sayers has rejected claims in a lawsuit by his wife that he defamed her and invaded her privacy in response to probes over an explicit photo.

Developer Robert Filippini, who is suspected of fraudulently receiving investor money from defunct Keystone Asset Management, is seeking to appeal an extension of freezing orders over family trusts that hold property and several luxury cars.

Australian designer Katie Taylor has won her High Court appeal in a fight with pop star Katy Perry over the right to trade mark her name, with the court saying a Full Court ruling in Perry's favour "rewarded the wrongdoers".

A judge has granted the first-ever application to vary a contingency fee in a class action that has yet to reach settlement or judgment, but has warned his decision doesn't set a precedent for “routine variation” of group costs orders. 

Developer Robert Filippini, who is suspected of fraudulently receiving investor money from defunct Keystone Asset Management, is seeking to appeal an extension of freezing orders over family trusts that hold property and several luxury cars.

Pharmacor wants to amend its defence in AstraZeneca's suit over the Australian drug maker's plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.